Market Cap 185.95B
Revenue (ttm) 36.75B
Net Income (ttm) 7.71B
EPS (ttm) N/A
PE Ratio 15.96
Forward PE 15.72
Profit Margin 20.98%
Debt to Equity Ratio 6.31
Volume 2,201,400
Avg Vol 2,581,374
Day's Range N/A - N/A
Shares Out 539.69M
Stochastic %K 27%
Beta 0.47
Analysts Sell
Price Target $357.84

Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of my...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 805 447 1000
Fax: 805 447 1010
Address:
One Amgen Center Drive, Thousand Oaks, United States
grampslol
grampslol Apr. 25 at 11:52 AM
Poor $MNKD pumper clan... smh... deluding himself as he tries to deceive others about the Afizzle company...a delusional cultist indeed... $PFE $JNJ $AMGN
0 · Reply
clan
clan Apr. 25 at 7:39 AM
$MNKD For the good of all mankind. $JNJ $PFE $AMGN
0 · Reply
UsingAGodAlgorithm
UsingAGodAlgorithm Apr. 24 at 10:17 PM
$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile We also covered these names. $DIS $C $AMGN $AXP
0 · Reply
BullProphet
BullProphet Apr. 24 at 3:34 PM
The obesity space is starting to look like a full-on pipeline war between pharma giants… $ABBV is effectively building an “options portfolio” in obesity — not just one asset, but multiple shots on goal across mechanisms, formats, and durations. Same strategic logic applies (to varying degrees) for $AMGN, $NVO, and the rest of the field — but execution paths are diverging fast. Key divide right now: Importing molecules from China with limited Western tolerability + trial consistency data vs. building fully US-validated clinical pipelines with cleaner regulatory paths and higher predictability. The current read-through from $NVO vs $LLY oral data is important — it’s highlighting where differentiation actually matters: tolerability + mechanism efficiency + adherence, not just headline efficacy. Does VKTX share everything to maximize market validation… or optimize for strategic positioning first? That answer may shape repricing across the entire obesity stack.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 24 at 1:57 AM
It appears analysts have updated their $NBIX analysts as NBIX analyst consensus before the $SLNO acquisition was announced is higher almost exactly by the revenue forecast SLNO management provided NBIX. The graph compares NBIX 10-year analyst consensus to the 10-year revenue forecast prepared by $HZNP mgmt/BOD & provided $AMGN when Amgen acquired HZNP for an enterprise value of $28.2B. NBIX's market cap is $13.1B while it appears NBIX's $2.6B cash balance at 12/31/26 was used to buy SLNO for an EV of $2.44B. NBIX management will, eventually, need to consider alternate strategies to enhance shareholder value because NBIX has not traded at revenue multiples consistent with its peers in at least 2 years. This is not investment advice. $XBI
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 23 at 11:26 PM
REGN Becomes Final Major Drugmaker To Sign Trump’s Drug Pricing Pledge $REGN $LLY $GSK $ABBV $AMGN https://stocktwits.com/news/equity/markets/regn-becomes-final-major-drugmaker-to-sign-trump-s-drug-pricing-pledge/cZBQQQSReT5
0 · Reply
JuicyMoliere
JuicyMoliere Apr. 23 at 10:02 PM
$AMGN Bunch of French Californians that whine their way to results. These guys are the most incompetent project managers on the planet. Takes them twice as long as the average contract development team in pharma or device to do the simplest tasks. Nothing novel in their pipeline. Hacks with more $$$ than sense.
0 · Reply
Mr_pippin
Mr_pippin Apr. 23 at 11:39 AM
$AMGN held that flush
0 · Reply
clan
clan Apr. 23 at 11:35 AM
$MNKD Advancing pipeline. Coming to market. Blockbuster. Revenue enhancing. Cash-generating. Market-capturing. Patient-helping. For the good of all mankind and Mannkind. 👀 $AMGN $MRK $JNJ 👀
0 · Reply
profit_guru
profit_guru Apr. 22 at 2:39 PM
$AMGN - expect blockbuster earnings next week with repatha growth surpassing estimates
0 · Reply
Latest News on AMGN
Amgen's lung cancer drug tarlatamab wins China approval

Apr 10, 2026, 4:10 AM EDT - 16 days ago

Amgen's lung cancer drug tarlatamab wins China approval


FDA Says Amgen's Tavneos Linked to Liver Injuries, Deaths

Mar 31, 2026, 11:16 AM EDT - 26 days ago

FDA Says Amgen's Tavneos Linked to Liver Injuries, Deaths


Amgen Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 9:20 AM EDT - 6 weeks ago

Amgen Transcript: Leerink Global Healthcare Conference 2026


AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND

Mar 4, 2026, 4:01 PM EST - 7 weeks ago

AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND


Amgen Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 1:10 PM EST - 7 weeks ago

Amgen Transcript: TD Cowen 46th Annual Health Care Conference


Why Amgen Stock Is Paying Off Big For Long-Term Investors

Feb 4, 2026, 10:50 AM EST - 2 months ago

Why Amgen Stock Is Paying Off Big For Long-Term Investors


Amgen Earnings Call Transcript: Q4 2025

Feb 3, 2026, 4:30 PM EST - 2 months ago

Amgen Earnings Call Transcript: Q4 2025


Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing

Jan 15, 2026, 4:40 PM EST - 3 months ago

Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing


Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

Jan 14, 2026, 12:36 PM EST - 3 months ago

Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses


Amgen CEO Bob Bradway goes one-on-one with Jim Cramer

Jan 13, 2026, 7:55 PM EST - 3 months ago

Amgen CEO Bob Bradway goes one-on-one with Jim Cramer


Amgen says MariTide helped trial patients maintain weight loss

Jan 12, 2026, 7:42 PM EST - 3 months ago

Amgen says MariTide helped trial patients maintain weight loss


Amgen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 PM EST - 3 months ago

Amgen Transcript: 44th Annual J.P. Morgan Healthcare Conference


The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

Jan 11, 2026, 7:40 AM EST - 3 months ago

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

CVX HD JNJ KO MRK NKE PG


Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs

Jan 7, 2026, 1:45 PM EST - 3 months ago

Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs


These three ‘Dogs of the Dow' stocks are must-own for 2026

Dec 31, 2025, 12:12 PM EST - 4 months ago

These three ‘Dogs of the Dow' stocks are must-own for 2026

HD VZ


Amgen Transcript: Citi Annual Global Healthcare Conference 2025

Dec 3, 2025, 1:45 PM EST - 5 months ago

Amgen Transcript: Citi Annual Global Healthcare Conference 2025


Amgen Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 10:00 AM EST - 5 months ago

Amgen Transcript: Evercore ISI 8th Annual HealthCONx Conference


Amgen Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 6 months ago

Amgen Earnings Call Transcript: Q3 2025


Amgen Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 9 months ago

Amgen Earnings Call Transcript: Q2 2025


Amgen Transcript: Status Update

Jun 23, 2025, 5:30 PM EDT - 10 months ago

Amgen Transcript: Status Update


Amgen Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 9:20 AM EDT - 11 months ago

Amgen Transcript: Jefferies Global Healthcare Conference 2025


Amgen Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 12:20 PM EDT - 1 year ago

Amgen Transcript: BofA Securities 2025 Healthcare Conference


Amgen Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Amgen Earnings Call Transcript: Q1 2025


Amgen Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 9:10 AM EST - 1 year ago

Amgen Transcript: TD Cowen 45th Annual Healthcare Conference


Amgen Earnings Call Transcript: Q4 2024

Feb 4, 2025, 4:30 PM EST - 1 year ago

Amgen Earnings Call Transcript: Q4 2024


Amgen Transcript: Citi's 2024 Global Healthcare Conference

Dec 5, 2024, 9:30 AM EST - 1 year ago

Amgen Transcript: Citi's 2024 Global Healthcare Conference


Amgen Transcript: Study Result

Nov 26, 2024, 8:00 AM EST - 1 year ago

Amgen Transcript: Study Result


Amgen Transcript: UBS Global Healthcare Conference 2024

Nov 13, 2024, 1:15 PM EST - 1 year ago

Amgen Transcript: UBS Global Healthcare Conference 2024


Amgen Earnings Call Transcript: Q3 2024

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Amgen Earnings Call Transcript: Q3 2024


Amgen Transcript: Study Update

Sep 24, 2024, 4:30 PM EDT - 1 year ago

Amgen Transcript: Study Update


Amgen Transcript: Wells Fargo 2024 Healthcare Conference

Sep 5, 2024, 9:30 AM EDT - 1 year ago

Amgen Transcript: Wells Fargo 2024 Healthcare Conference


Amgen Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Amgen Earnings Call Transcript: Q2 2024


Amgen Transcript: Jefferies 2024 Global Healthcare Conference

Jun 6, 2024, 9:00 AM EDT - 2 years ago

Amgen Transcript: Jefferies 2024 Global Healthcare Conference


Amgen Transcript: Status Update

May 20, 2024, 4:00 PM EDT - 2 years ago

Amgen Transcript: Status Update


Amgen Transcript: BofA Securities 2024 Health Care Conference

May 14, 2024, 12:20 PM EDT - 2 years ago

Amgen Transcript: BofA Securities 2024 Health Care Conference


Amgen Earnings Call Transcript: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Amgen Earnings Call Transcript: Q1 2024


Amgen Transcript: Investor Update

Feb 22, 2024, 4:00 PM EST - 2 years ago

Amgen Transcript: Investor Update


Amgen Earnings Call Transcript: Q4 2023

Feb 6, 2024, 4:30 PM EST - 2 years ago

Amgen Earnings Call Transcript: Q4 2023


Amgen Earnings Call Transcript: Q3 2023

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Amgen Earnings Call Transcript: Q3 2023


Amgen Transcript: Status Update

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Amgen Transcript: Status Update


Amgen Transcript: Bank of America Global Healthcare Conference

Sep 14, 2023, 6:40 AM EDT - 2 years ago

Amgen Transcript: Bank of America Global Healthcare Conference


Amgen Transcript: Citi Global Healthcare Conference

Sep 7, 2023, 1:00 PM EDT - 2 years ago

Amgen Transcript: Citi Global Healthcare Conference


Amgen Transcript: Citi’s 18th Annual BioPharma Conference

Sep 7, 2023, 1:00 PM EDT - 2 years ago

Amgen Transcript: Citi’s 18th Annual BioPharma Conference


Amgen Earnings Call Transcript: Q2 2023

Aug 3, 2023, 4:30 PM EDT - 2 years ago

Amgen Earnings Call Transcript: Q2 2023


Amgen Earnings Call Transcript: Q1 2023

Apr 27, 2023, 4:30 PM EDT - 3 years ago

Amgen Earnings Call Transcript: Q1 2023


Amgen Transcript: Oppenheimer Healthcare Conference

Mar 13, 2023, 2:00 PM EDT - 3 years ago

Amgen Transcript: Oppenheimer Healthcare Conference


Amgen Transcript: Cowen Health Care Conference

Mar 8, 2023, 11:10 AM EST - 3 years ago

Amgen Transcript: Cowen Health Care Conference


Amgen Earnings Call Transcript: Q4 2022

Jan 31, 2023, 4:30 PM EST - 3 years ago

Amgen Earnings Call Transcript: Q4 2022


Amgen Transcript: JPMorgan Healthcare Conference

Jan 9, 2023, 6:45 PM EST - 3 years ago

Amgen Transcript: JPMorgan Healthcare Conference


Amgen Transcript: M&A Announcement

Dec 12, 2022, 8:00 AM EST - 3 years ago

Amgen Transcript: M&A Announcement


Amgen Transcript: Study Update

Dec 5, 2022, 8:00 AM EST - 3 years ago

Amgen Transcript: Study Update


Amgen Transcript: Study Update

Nov 7, 2022, 6:00 PM EST - 3 years ago

Amgen Transcript: Study Update


Amgen Earnings Call Transcript: Q3 2022

Nov 3, 2022, 11:45 AM EDT - 3 years ago

Amgen Earnings Call Transcript: Q3 2022


Amgen Transcript: Study Update

Aug 8, 2022, 12:00 PM EDT - 4 years ago

Amgen Transcript: Study Update


Amgen Earnings Call Transcript: Q2 2022

Aug 3, 2022, 8:54 PM EDT - 4 years ago

Amgen Earnings Call Transcript: Q2 2022


Amgen Earnings Call Transcript: Q1 2022

Apr 27, 2022, 10:16 AM EDT - 4 years ago

Amgen Earnings Call Transcript: Q1 2022


Amgen Earnings Call Transcript: Q4 2021

Feb 8, 2022, 2:51 PM EST - 4 years ago

Amgen Earnings Call Transcript: Q4 2021


Amgen Transcript: Investor Update

Feb 8, 2022, 8:00 AM EST - 4 years ago

Amgen Transcript: Investor Update


Amgen Earnings Call Transcript: Q3 2021

Nov 1, 2021, 8:00 PM EDT - 4 years ago

Amgen Earnings Call Transcript: Q3 2021


Amgen Transcript: Study Update

Oct 4, 2021, 8:30 AM EDT - 4 years ago

Amgen Transcript: Study Update


Amgen Transcript: Study Update

Sep 16, 2021, 8:30 AM EDT - 5 years ago

Amgen Transcript: Study Update


Amgen Earnings Call Transcript: Q2 2021

Aug 3, 2021, 12:00 AM EDT - 5 years ago

Amgen Earnings Call Transcript: Q2 2021


Amgen Transcript: FDA Announcement

Jun 1, 2021, 8:00 AM EDT - 5 years ago

Amgen Transcript: FDA Announcement


Amgen Earnings Call Transcript: Q1 2021

Apr 27, 2021, 5:52 AM EDT - 5 years ago

Amgen Earnings Call Transcript: Q1 2021


Amgen Transcript: M&A Announcement

Mar 4, 2021, 12:50 PM EST - 5 years ago

Amgen Transcript: M&A Announcement


Amgen Earnings Call Transcript: Q4 2020

Feb 2, 2021, 5:00 PM EST - 5 years ago

Amgen Earnings Call Transcript: Q4 2020


Amgen Transcript: Study Result

Jan 29, 2021, 8:00 PM EST - 5 years ago

Amgen Transcript: Study Result


Amgen Transcript: Study Update

Dec 8, 2020, 4:00 PM EST - 5 years ago

Amgen Transcript: Study Update


Amgen Earnings Call Transcript: Q3 2020

Oct 28, 2020, 5:00 PM EDT - 5 years ago

Amgen Earnings Call Transcript: Q3 2020


Amgen Earnings Call Transcript: Q2 2020

Jul 28, 2020, 5:00 PM EDT - 6 years ago

Amgen Earnings Call Transcript: Q2 2020


Amgen Earnings Call Transcript: Q1 2020

Apr 30, 2020, 5:30 PM EDT - 6 years ago

Amgen Earnings Call Transcript: Q1 2020


Amgen Transcript: Collaboration

Apr 9, 2020, 11:00 AM EDT - 6 years ago

Amgen Transcript: Collaboration


Amgen Earnings Call Transcript: Q4 2019

Jan 30, 2020, 5:00 PM EST - 6 years ago

Amgen Earnings Call Transcript: Q4 2019


Amgen Transcript: Collaboration

Oct 31, 2019, 5:00 PM EDT - 7 years ago

Amgen Transcript: Collaboration


Amgen Earnings Call Transcript: Q3 2019

Oct 29, 2019, 5:00 PM EDT - 7 years ago

Amgen Earnings Call Transcript: Q3 2019


Amgen Transcript: M&A Announcement

Aug 26, 2019, 8:00 AM EDT - 7 years ago

Amgen Transcript: M&A Announcement


Amgen Earnings Call Transcript: Q2 2019

Jul 30, 2019, 5:30 PM EDT - 7 years ago

Amgen Earnings Call Transcript: Q2 2019


Amgen Earnings Call Transcript: Q1 2019

Apr 30, 2019, 5:00 PM EDT - 7 years ago

Amgen Earnings Call Transcript: Q1 2019


Amgen Earnings Call Transcript: Q4 2018

Jan 29, 2019, 5:00 PM EST - 7 years ago

Amgen Earnings Call Transcript: Q4 2018


Amgen Earnings Call Transcript: Q3 2018

Oct 30, 2018, 5:00 PM EDT - 8 years ago

Amgen Earnings Call Transcript: Q3 2018


Amgen Transcript: Investor Update

Oct 24, 2018, 5:00 PM EDT - 8 years ago

Amgen Transcript: Investor Update


Amgen Earnings Call Transcript: Q2 2018

Jul 26, 2018, 5:00 PM EDT - 8 years ago

Amgen Earnings Call Transcript: Q2 2018


Amgen Transcript: FDA Announcement

May 18, 2018, 9:00 AM EDT - 8 years ago

Amgen Transcript: FDA Announcement


Amgen Earnings Call Transcript: Q1 2018

Apr 24, 2018, 5:00 PM EDT - 8 years ago

Amgen Earnings Call Transcript: Q1 2018


grampslol
grampslol Apr. 25 at 11:52 AM
Poor $MNKD pumper clan... smh... deluding himself as he tries to deceive others about the Afizzle company...a delusional cultist indeed... $PFE $JNJ $AMGN
0 · Reply
clan
clan Apr. 25 at 7:39 AM
$MNKD For the good of all mankind. $JNJ $PFE $AMGN
0 · Reply
UsingAGodAlgorithm
UsingAGodAlgorithm Apr. 24 at 10:17 PM
$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile We also covered these names. $DIS $C $AMGN $AXP
0 · Reply
BullProphet
BullProphet Apr. 24 at 3:34 PM
The obesity space is starting to look like a full-on pipeline war between pharma giants… $ABBV is effectively building an “options portfolio” in obesity — not just one asset, but multiple shots on goal across mechanisms, formats, and durations. Same strategic logic applies (to varying degrees) for $AMGN, $NVO, and the rest of the field — but execution paths are diverging fast. Key divide right now: Importing molecules from China with limited Western tolerability + trial consistency data vs. building fully US-validated clinical pipelines with cleaner regulatory paths and higher predictability. The current read-through from $NVO vs $LLY oral data is important — it’s highlighting where differentiation actually matters: tolerability + mechanism efficiency + adherence, not just headline efficacy. Does VKTX share everything to maximize market validation… or optimize for strategic positioning first? That answer may shape repricing across the entire obesity stack.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 24 at 1:57 AM
It appears analysts have updated their $NBIX analysts as NBIX analyst consensus before the $SLNO acquisition was announced is higher almost exactly by the revenue forecast SLNO management provided NBIX. The graph compares NBIX 10-year analyst consensus to the 10-year revenue forecast prepared by $HZNP mgmt/BOD & provided $AMGN when Amgen acquired HZNP for an enterprise value of $28.2B. NBIX's market cap is $13.1B while it appears NBIX's $2.6B cash balance at 12/31/26 was used to buy SLNO for an EV of $2.44B. NBIX management will, eventually, need to consider alternate strategies to enhance shareholder value because NBIX has not traded at revenue multiples consistent with its peers in at least 2 years. This is not investment advice. $XBI
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 23 at 11:26 PM
REGN Becomes Final Major Drugmaker To Sign Trump’s Drug Pricing Pledge $REGN $LLY $GSK $ABBV $AMGN https://stocktwits.com/news/equity/markets/regn-becomes-final-major-drugmaker-to-sign-trump-s-drug-pricing-pledge/cZBQQQSReT5
0 · Reply
JuicyMoliere
JuicyMoliere Apr. 23 at 10:02 PM
$AMGN Bunch of French Californians that whine their way to results. These guys are the most incompetent project managers on the planet. Takes them twice as long as the average contract development team in pharma or device to do the simplest tasks. Nothing novel in their pipeline. Hacks with more $$$ than sense.
0 · Reply
Mr_pippin
Mr_pippin Apr. 23 at 11:39 AM
$AMGN held that flush
0 · Reply
clan
clan Apr. 23 at 11:35 AM
$MNKD Advancing pipeline. Coming to market. Blockbuster. Revenue enhancing. Cash-generating. Market-capturing. Patient-helping. For the good of all mankind and Mannkind. 👀 $AMGN $MRK $JNJ 👀
0 · Reply
profit_guru
profit_guru Apr. 22 at 2:39 PM
$AMGN - expect blockbuster earnings next week with repatha growth surpassing estimates
0 · Reply
johns45
johns45 Apr. 21 at 9:04 PM
$AMGN Rapatha scripts are off the chart!!!!They are finding that the drug significantly lowers chance of cardiac arrest while reversing cardio vascular disease.....This is a $500 stock.
0 · Reply
EdbergInvest
EdbergInvest Apr. 21 at 9:00 PM
$AMGN oversold LT Bull
0 · Reply
profit_guru
profit_guru Apr. 21 at 5:09 PM
$AMGN - rotation back to healthcare will resume tomorrow if Iran deal doesn’t go through…buy the dip…near term 360…imo
0 · Reply
Arcides
Arcides Apr. 21 at 2:37 PM
$GILD $AMGN $LLY these health care names are weak...
0 · Reply
profit_guru
profit_guru Apr. 21 at 1:55 PM
$AMGN - as usual this will close green …ridiculous sale of strong well run pharma company with solid growth….night close above 350…imo
0 · Reply
geffaxp
geffaxp Apr. 20 at 7:42 PM
$JNJ $PFE $MRK $LLY $AMGN REGARDING FBCD AND ITS MUSHROOM CULTURE: I BOUGHT 5 MILLION SHRS OF FBC Holding, Inc. IN FEBRUARY. "(FBCD) Acquires Mushroom Madness to Accelerate Entry Into Explosive Mushroom Wellness Market." ACCESS Newswire. With the global functional mushroom industry projected to surge past $22.3 billion by 2030, fueled by a 9.3%+ CAGR, FBCD's strategic acquisition positions the company at the forefront of one of the fastest-growing wellness sectors in America - especially as Oregon leads the nation in legalized therapeutic mushroom innovation." FBCD: IT'S A STRONG BUY FOR THE FUTURE. THE MUSHROOM FRENZY IS OUT THERE AND BUILDING FAST. I'M ALWAYS RIGHT, BUT I'M ALWAYS EARLY. ALL THE BETTER. 02/09/2026. BULLISH TWO DAYS AGO: Joe Rogan joins Trump to sign order allowing psychedelic drug research by Sarah Davis - 04/18/26 10:19 AM ET IT'S STARTING. TOLD YA. Bullish
0 · Reply
OpenOutcrier
OpenOutcrier Apr. 20 at 12:55 PM
$ZLAB (+2.4% pre) Zai Lab (ZLAB), Amgen $AMGN Partner to Evaluate Combination Lung Cancer Therapy; Zai Lab stock rises on positive trial data for cancer drug https://ooc.bz/l/99292
0 · Reply
Game_Day
Game_Day Apr. 19 at 7:52 AM
Over 5000% $TSLA $MP $WYNN $CAVA $AMGN what next
0 · Reply
clan
clan Apr. 18 at 8:21 AM
$MNKD Nintedanib DPI - coming soon to a pharmacy near you! For the good of all Mannkind and mankind! $MRK $AMGN
0 · Reply
UsingAGodAlgorithm
UsingAGodAlgorithm Apr. 17 at 11:24 PM
$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile We also covered these names. $DIS $C $AMGN $AXP
0 · Reply
Pearl_Power
Pearl_Power Apr. 17 at 4:29 PM
$AMGN looks like inverted HNS at former ATH
0 · Reply
topstockalerts
topstockalerts Apr. 16 at 8:53 PM
OpenAI announced GPT-Rosalind, a new AI model designed to support research in biology, drug discovery, and translational medicine. The model is optimized for scientific workflows, integrating tool use with capabilities in chemistry, protein engineering, and genomics, where drug development timelines typically span 10–15 years. It is being released as a research preview across ChatGPT, Codex, and the API for qualified users under OpenAI’s trusted access program, alongside a new Life Sciences extension that connects to over 50 scientific tools and datasets. OpenAI is collaborating with partners including Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific to apply the model across research workflows. Named after Rosalind Franklin, the model demonstrated strong performance in benchmarks, outperforming GPT-5.4 in several research tasks and achieving top-tier results in RNA sequence prediction tests with Dyno Therapeutics. $MSFT $AMGN $MRNA
0 · Reply